Answers are grounded in this paper and cite their sources.
Objectives: Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare, highly aggressive malignancy of immature hematopoietic cells that typically affects healthy elderly patients and has a known skin tropism. Immunophenotyping is particularly valuable in establishing the diagnosis: bright, homogeneous expression of CD123, with coexpression of CD4 and CD56, is virtually pathognomonic. Cytogenetics typically reveals complex karyotypes. We report a case of BPDCN with an aberrant immunophenotypic profile. Methods: The patient is a 75-year-old man previously diagnosed with peripheral T-cell lymphoma, based on a bone marrow biopsy at an outside institution that showed extensive involvement by malignant cells positive for CD4 by immunohistochemistry (IHC). He presented to Mobile Infirmary Medical Center with pancytopenia and new onset lymphadenopathy. Lymph node biopsy demonstrated a proliferation of medium to large cells with fine chromatin, prominent nucleoli, and scanty basophilic cytoplasm. Flow cytometry demonstrated a population of cells with expression of CD45 (moderate), CD4, CD22, CD38, and CD71 (dim). The cells were negative for CD56, other B- and T-cell markers, and surface and cytoplasmic light chains. IHC showed malignant cells positive for CD123, CD43, Bcl-2, TdT (rare cells), and Ki67 (30%); and negative for CD30, CD45RO, CD79a, CD138, Bcl-6, ALK-1, MUM-1, and PAX-5. Cytogenetic fluorescence in situ hybridization studies revealed unexpected abnormalities involving MYC , with no evidence of other rearrangement. Conclusions: BPDCN is an aggressive neoplasm with a distinct immunophenotype. However, atypical phenotypes can be seen, including lack of CD56 expression and/or expression of T- or B-cell markers, which can lead to misdiagnosis of lymphoma. Aberrant immunophenotype and cytogenetics should not rule out the diagnosis, as prompt identification and targeted treatment with new chemotherapeutic options, such as CD123-directed therapy and/or stem cell transplant may improve survival.
No takes yet. Share an insight, caveat, or question.
Harley et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: